A striking number of the FDA-approved peptide drugs covered on this site, including teduglutide, setmelanotide, icatibant, and afamelanotide, share something besides their chemistry: they were all developed under orphan drug designation. It's a program that shapes which rare-disease peptides make it to market at all.
What the Orphan Drug Act Does
The Orphan Drug Act, passed in 1983, created a formal pathway for the FDA to encourage development of treatments for rare diseases, defined under the act as conditions affecting fewer than 200,000 people in the United States, or, in some cases, a larger population where there's no reasonable expectation that sales would recover the cost of development. Before the law existed, there was little financial incentive for drug companies to develop treatments for small patient populations, since the research and trial costs for a drug are largely the same whether it will serve a few thousand patients or a few million. The FDA's Office of Orphan Products Development administers the designation.
What a Company Actually Gets
Orphan drug designation comes with several concrete benefits. The most significant is seven years of market exclusivity for that specific orphan indication after approval, a separate protection from patent exclusivity that can apply even if a drug's patents have expired or been successfully challenged. Companies also get a tax credit for qualified clinical trial costs (reduced from 50% to 25% by the 2017 Tax Cuts and Jobs Act), a waiver of the FDA's standard prescription drug user fee for the marketing application, and eligibility for FDA grant funding that helps offset trial costs.
What It Doesn't Guarantee
Orphan drug designation is not an approval, and it says nothing about whether a drug will ultimately prove safe or effective. It's granted earlier in development, often around the time a company starts clinical trials, based on the target disease's prevalence and the drug's potential, not on efficacy data. A designated drug still has to go through the same clinical trial and FDA review process, including an IND application and, typically, a Biologics License Application for a peptide, covered in more detail in this site's dedicated explainer. Many orphan-designated drugs never reach approval.
Why Peptide Drugs Show Up Here So Often
Peptide drugs are disproportionately represented among orphan-designated approvals for a structural reason: many peptides are naturally occurring hormones or close analogs of them, and the conditions they're best suited to treat, like genetic forms of obesity, hereditary angioedema, or short bowel syndrome, tend to be rare by definition. A peptide that mimics a hormone affecting a specific receptor pathway is often a precise fit for a narrow, well-defined rare disease rather than a broad one, which is exactly the profile the orphan drug program was designed around.
Examples on This Site
Teduglutide (short bowel syndrome), setmelanotide (rare genetic obesity syndromes), icatibant (hereditary angioedema), and afamelanotide (erythropoietic protoporphyria) are all FDA-approved peptides covered elsewhere on this site that moved through development with orphan drug designation attached to their rare-disease indication. In each case, the designation helped make the economics of developing a treatment for a very small patient population viable in the first place.
The Bottom Line
Orphan drug designation is a financial and regulatory tool, not a safety or efficacy signal, and it shouldn't be read as either. What it reliably tells you is that a drug targets a disease the FDA has recognized as rare, and that the company developing it is getting specific incentives to do so, incentives that have made a meaningful share of the peptide drugs covered on this site possible at all.